MedTrace Logo

Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment

NCT02965443 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-02-11

No results posted yet for this study

Summary

To perform a study that investigates the effectiveness of adding the SGLT2 inhibitor dapagliflozin + the dipeptidyl peptidase 4 (DPP-4) inhibitor saxagliptin vs placebo to revert from a BBIT regimen to a BOT regimen in patients with type 2 diabetes.

Conditions

Interventions

DRUG

Dapagliflozin 10 mg + Saxagliptin 5 mg

24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg

DRUG

Placebo 1 10 mg + Placebo 2 5 mg

24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-02
Primary Completion
2020-02-03
Completion
2020-02-03

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02965443 on ClinicalTrials.gov